Journal of Clinical Oncology
Articles in this Issue
A phase 1 study of docetaxel in combination with 177-lutetium-PSMA-I&T in patients with metastatic castration-resistant prostate cancer.
TPS281 Background: Radioligand therapy targeting prostate-specific membrane antigen (PSMA) with 177-Lutetium-labeled ligan...
Post-chemotherapy retroperitoneal lymph node dissection for patients with metastatic pure seminoma.
611 Background: Post-chemotherapy retroperitoneal lymph node dissection (pcRPLND) for metastatic testicular seminoma is re...
Characterizing frailty and its drivers in bladder cancer using machine learning-derived vulnerability and resource phenotypes.
724 Background: Frailty predicts surgical complications and mortality in bladder cancer. Guidelines endorse evaluating for...
Real-world clinical outcomes among patients with localized prostate cancer (LPC) undergoing radical prostatectomy (RP).
343 Background: RP is a curative option for LPC. While prognosis is generally favorable, patients with high-risk (HR) feat...
Association of a post-prostatectomy digital pathology–based multimodal artificial intelligence (MMAI) biomarker with nodal and extrapelvic metastasis on PET/CT at the time of biochemical recurrence and event-free survival following salvage radiotherapy.
378 Background: Clinical prostate cancer variables have limited ability to predict patterns of recurrence or outcomes afte...
Next-generation sequencing of bladder and upper tract micropapillary variant urothelial carcinoma patients and associated clinical outcomes.
828 Background: Micropapillary variant urothelial carcinoma (MPUC) is a histologically and genotypically defined variant o...
Real world outcomes comparing the use of GLP-1 agonists in patients with renal cell carcinoma (RCC) and comorbid obesity: A propensity score matched analysis from Global Federated Health Research Network.
484 Background: Renal cell carcinoma (RCC) is the most common type of urogenital cancer. Lifestyle and metabolic risk fact...
Adding metformin to androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC): Quality of life (QoL) results from STAMPEDE.
135 Background: ADT, the standard treatment for mHSPC, induces metabolic side effects that impact QoL. In the STAMPEDE tri...
Toward noninvasive genomic profiling in muscle-invasive bladder cancer using quantitative CT texture analysis.
825 Background: Urothelial bladder cancer exhibits substantial pathological, molecular, and clinical heterogeneity. Genomi...
Neoadjuvant tislelizumab in combination with disitamab vedotin (RC48) followed by distal ureterectomy for patients with HER-2 expressing lower segment ureteral carcinoma (LSUC): A single-arm, phase II, single-center study.
765 Background: As a special subtype of upper tract urothelial carcinoma (UTUC), lower segment ureteral carcinoma (LSUC) i...
Intismeran autogene (V940/mRNA-4157) plus bacillus Calmette-Guérin (BCG) versus BCG alone for high-risk non–muscle-invasive bladder cancer: The phase 2 INTerpath-011 study.
TPS882 Background: Transurethral resection of a bladder tumor (TURBT) followed by intravesical BCG is the standard of care...
Clinical validity of FoundationOne CDx assay to identify <i>HRR</i> -positive or <i>BRCA</i> -positive mCSPC patients in the phase 3 AMPLITUDE study.
166 Background: AMPLITUDE, a Phase 3, randomized, double-blind, placebo-controlled trial, evaluated the safety and efficac...
Body composition metrics and clinical outcomes for patients with metastatic castration-resistant prostate cancer (mCRPC) treated with lutetium-177–PSMA-617.
241 Background: Lutetium-177 ( 177 Lu)–PSMA-617 is a radioligand therapy that can...
Real-world comparative effectiveness of first-line (1L) cabozantinib (C) versus cabozantinib with nivolumab (C+N) in patients (pts) with metastatic papillary renal cell carcinoma (mPRCC).
461 Background: mPRCC is the most common non-clear cell renal cell carcinoma (RCC). Standard of care options include both...
From bladder to upper urinary tract: Unveiling the epidemiological dynamics of urothelial carcinoma.
677 Background: Urothelial carcinoma (UC), encompassing bladder cancer, ureteral cancer, and renal pelvic cancer, exhibits...
Radiation dose tailoring guided by enhanced targeting (RadTARGET): A multi-center randomized controlled trial.
TPS409 Background: Definitive radiation therapy for localized prostate cancer with dose intensification and/or focal boost...
Cadonilimab plus lenvatinib in advanced renal cell carcinoma: Interim analysis of a prospective, multi-cohort phase II study.
501 Background: Renal cell carcinoma is a common urological malignancy with poor prognosis in advanced stages, creating a...
Long-term effectiveness and safety of avelumab first-line maintenance (1LM) in locally advanced or metastatic urothelial carcinoma (la/mUC): Updated systematic literature review (SLR) and meta-analysis (MA).
678 Background: Avelumab 1LM is the standard of care for patients (pts) with la/mUC without progression after 1L platinum-...
Final overall survival results from the EORTC 1333/PEACE-3 trial: Enzalutamide with or without radium-223 in metastatic castration-resistant prostate cancer.
15 Background: In EORTC1333.PEACE-3 the combination of enzalutamide and radium-223 (ENZ/RAD) prolonged rPFS and OS (interi...
Clinical outcomes in patients with locally advanced or metastatic urothelial cancer (la/mUC) in France treated with avelumab first-line maintenance (1LM): A real-world observational study using the French National Healthcare Database (Système National des Données de Santé [SNDS]).
740 Background: Avelumab 1LM is a recommended treatment for patients with la/mUC without disease progression following 1L...
[ <sup>225</sup> Ac]Ac-AKY-1189, a Nectin-4 targeted radiopharmaceutical, in patients with previously treated locally advanced or metastatic solid tumors: Phase 1b Nectinium-2 study.
TPS902 Background: Nectin-4 is a clinically validated target in metastatic urothelial cancer and is over-expressed in mult...
Incidence and co-occurrence of targetable key genomic alterations (GenAlt) in metastatic prostate cancer (mPC): Preliminary results from the prostate cancer cohort of the FPG500 program.
249 Background: PC is the most common male malignancy worldwide, associated with significant morbidity and mortality. GenA...
Concurrent use of angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB) in patients (pts) with advanced urothelial carcinoma (UC) receiving enfortumab vedotin (EV) plus pembrolizumab (P) therapy.
759 Background: Some advanced UC pts treated with EV plus P therapy have primary refractory disease or develop progressive...
Changes in CTCAE v6: Effect on dose-escalation and dose-limiting toxicity with repeat analysis of recent clinical trials.
143 Background: Several therapeutic modalities for cancer have associated myelosuppression. Amongst changes in CTCAE v6, g...
Real-world outcomes of [ <sup>177</sup> Lu]Lu-PSMA-617 ( <sup>177</sup> Lu-PSMA-617)in taxane-naïve patients with metastatic castration-resistant prostate cancer (mCRPC): A prostate cancer disease observation (PRECISION) data platform analysis.
81 Background: In the PSMAfore clinical trial, 177 Lu-PSMA-617 achieved a PSA50 (d...